ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
Status:
COMPLETED
Trial end date:
2024-09-09
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.